BreborowiczA., BalaskasE., OreopoulosG.D., MartisL., SerkesK., OreopoulosD.G.In vitro study of the effect of osmotic solutes on the interactions between cells from the peritoneum and peritoneal cavity.Perit Dial Int.1994; 14: 149–54.
3.
BreborowiczA., RodelaH., KaronJ., MartisL., OreopoulosD.G.In vitro simulation of the effect of peritoneal dialysis solution on mesothelial cells.Am J Kidney Dis.1997; 29: 404–9.
4.
de FijterC.W.H., VerbrughH.A., PetersE.D.J., OeP.L., van der MeulenJ., VerhoefJ.In vivo exposure to the currently available peritoneal dialysis fluids decreases the function of peritoneal macrophages in CAPD.Clin Nephrol.1993; 39: 75–80.
5.
WangT., ChenC., HeimbürgerO., WaniewskiJ., BergströmJ., LindholmB.Hyaluronan decreases peritoneal fluid absorption in peritoneal dialysis.J Am Soc Nephrol.1997; 8: 1915–20.
6.
GallimoreB., GagnonR., RichardsG.K.Response of chronic renal failure mice to peritoneal Staphylococcus epidermidis challenge: Impact of repeated peritoneal installation of dialysis solution.Am J Kidney Dis.1989; 14: 184–95.
7.
WuG., Wieczorowska-TobisK., PolubinskaA., KorybalskaK., FilasV., TamP.N-acetylglucosamine changes permeability of peritoneum during chronic peritoneal dialysis in rats.Perit Dial Int.1998; 18: 217–24.
8.
GotloibL., WajsbrotV., ShostakA., KushnierR.Acute and long-term change observed in imprints of mouse mesothelium exposed to glucose-enriched, lactated, buffered dialysis solutions.Nephron.1995; 70: 466–77.
9.
Di PaoloN., GarosiG., PetriniG., MonaciG.Morphological and morphometric changes in mesothelial cells during peritoneal dialysis in the rabbit.Nephron.1996; 74: 594–9.
10.
WieslanderA.P., NordinM.K., MartinsonE., KjellstrandP.T.T., BobergU.C.Heat sterilised PD-fluids impair growth and inflammatory responses of cultured cell lines and human leukocytes.Clin Nephrol.1993; 39: 343–8.
11.
LiberekT., TopleyN., JörresA., PetersenM.M., ColesG.A., GahlG.M.Peritoneal dialysis fluid inhibition of polymorphonuclear leukocyte respiratory burst activation is related to the lowering of intracellular pH.Nephron.1993; 65: 260–5.
12.
DouvdevaniA., RapoportJ., KonfortyA., YulzariR., MoranA., ChaimovitzC.Intracellular acidification mediates the inhibitory effect of peritoneal dialysate on peritoneal macrophages.J Am Soc Nephrol.1995; 6: 207–13.
13.
GuoW., WillenR., AnderssonR., ParssonH., LiuX., JohanssonK.Morphological response of the peritoneum and spleen to intraperitoneal materials.Int J Artif Organs.1993; 16: 276–84.
14.
FracassoA., ColiU., LandiniS.Peritoneal sclerosis. Role of plasticizers.ASAIO Trans.1987; 33: 676–82.
15.
TsaiT-J, YenC-J, FangC-C, YangC-C, LeeP-H, YenT S.Effect of intraperitoneally administered agents on human peritoneal mesothelial cell growth.Nephron.1995; 71: 23–8.
16.
MackenzieR., WilliamsJ.D., MoselyA., ArgyleR., ColesG.A., HolmesC.J.In vivo exposure to bicarbonate/lactate (TBL) and bicarbonate (TB) buffered peritoneal dialysis fluids (PDF) improves peritoneal macrophage (PMΦ) function [Abstract].J Am Soc Nephrol.1996; 7: 1431.
17.
DaviesS.J., BryanJ., PhilippsL., RussellG.I.Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis.Nephrol Dial Transplant.1996; 11: 498–506.
18.
De AlvaroF., CastroM.J., DapenaF., BajoM.A., Fernandez-ReyesM.J., RomeroJ.R.Peritoneal resting is beneficial in peritoneal hyperpermeability and ultrafiltration failure. In: KhannaR., NolphK.D., ProwantB.F., TwardowskiZ.J., OreopoulosD.G., eds. Advances in Peritoneal Dialysis.Toronto: Peritoneal Dialysis Publications, 1993; 9: 56–61.
19.
NakayamaM., KawaguchiY., YamadaK., HasegawaT., TakazoeK., KatohN.Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD.Kidney Int.1997; 51: 182–6.
20.
EspositoC., GerlachH., BrettJ., SternD., VlassaraH.Endothelial receptor-mediated binding of glucose modified albumin is associated with increased mono layer permeability and modulation of cell surface coagulant properties.J Exp Med.1989; 170: 1387–407.
21.
FujimoriA., NaitoH., MiyazakiT., AzumaM., HashimotoS., HorikawaS.Elevation of interleukin 6 in the dialysate reflects peritoneal stimuli and deterioration of peritoneal function.Nephron.1996; 74: 471–2.
22.
HondaK., NittaK., HoritaH., YumuraW., NiheiH.Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure.Nephron.1996; 72: 171–6.
23.
MonquilM.C.J., ImholzA.L.T., StruijkD.G., KredietR.T.Does impaired trans cellular water transport contribute to net ultrafiltration failure during CAPD?Perit Dial Int.1995; 15: 42–8.
24.
Ho-dac-PannekeetM.M., StruijkD.G., KredietR.T.Improvement of trans cellular water transport by treatment with glucose free dialysate in patients with ultrafiltration failure [Abstract].Nephrol Dial Transplant.1996; 11: A255.
25.
MactierR.A., SprosenT.S., GokalR., WilliamsP.F., LindberghM., NaskR.Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain.Kidney Int.1998; 53: 1061–7.
26.
ColesG.A., GokalR., OggC., JaniF., O'DonoghueD., CancariniG.C.A randomized controlled trial of a bicarbonate and a bicarbonate/lactate-containing dialysis solution in CAPD.Perit Dial Int.1997; 17: 48–51.
27.
SchambyeH.T., PedersenF.B., WangP.Bicarbonate is not the ultimate answer to the biocompatibility problems of CAPD solutions: A cytotoxicity test of CAPD solutions and effluents. In: KhannaR., NolphK.D., ProwantB.F., TwardowskiZ.J., OreopoulosD.G., eds. Advances in Peritoneal Dialysis.Toronto: Peritoneal Dialysis Bulletin, 1992; 8: 41–6.
MistryC.D., GokalR., PeersE, and the Midas Study Group. A randomised multicentre clinical trial comparing isoosmolar icodextrin with hyperosmolar glucose solutions in CAPD.Kidney Int.1994; 46: 496–503.
30.
WieslanderA.P., DeppischR., SvenssonE., ForsbackG., SpeidelR., RippeB.In vitro biocompatibility of a heatsterilized, low-toxic and less acidic fluid for peritoneal dialysis.Perit Dial Int.1995; 15: 158–64.
31.
CookerL.A., LuneburgP., FaictD., ChooC., HolmesC.J.Reduced glucose degradation products in bicarbonate/ lactate-buffered peritoneal dialysis solutions produced in two-chambered bags.Perit Dial Int.1997; 17: 373–8.
32.
BreborowiczA., WieczorowskaK., WitowskiJ., MartisL., OreopoulosD.G.Phosphatidylcholine and chondroitin sulfate in peritoneal dialysis fluids to preserve membrane function.Perit Dial Int.1994; 14(Suppl 3): S139–44.
33.
BreborowiczA., WieczorowskaK., MartisL., OreopoulosD.G.Glycosaminoglycan chondroitin sulphate prevents loss of ultrafiltration during peritoneal dialysis in rats.Nephron.1994; 67: 346–50.
34.
BazzatoG., FracassoA., GambaroG., BaggioB.Use of glycosaminoglycans to increase efficiency of long-term continuous peritoneal dialysis.Lancet.1995; 346: 740–1.
